文献速递免疫规划卫生政策与健康促进

疫苗瓶监测器在中低收入国家的可获得性与使用情况:一项系统综述

Vaccine vial monitor availability and use in low- and middle-income countries: A systematic review.
PubMed 文献 · Vaccine · 2017-01-01

该研究系统综述了2005年以来英文和法文文献,评估中低收入国家疫苗瓶监测器(VVM)的可获得性与使用情况,发现VVM的可获得性和使用受疫苗多来源采购及招标文件中VVM纳入疫苗规格程度的影响,卫生工作者和决策者对VVM认知较高,但国家监管机构和采购机构能力薄弱可能影响需求,全球可获得性和国家需求依赖WHO和UNICEF等政策机构的政策声明和建议。

要点

  • VVM的可获得性和使用受疫苗多来源采购及招标文件纳入VVM规格程度影响。
  • 卫生工作者和决策者对VVM及其对免疫规划影响的认知较高。
  • 国家监管机构和采购机构能力薄弱可能影响VVM需求,国家需求依赖WHO和UNICEF等政策建议。

核心结论

  • 全球VVM可获得性和国家需求依赖WHO和UNICEF等关键政策机构关于VVM的政策声明和建议。
  • 尽管符合Gavi资格的国家可获得带VVM标签的疫苗,但纳入率常低于100%。
  • 关键国家机构如NRA和NPA能力薄弱似乎是 contributing 因素,其他因素包括采购关于将VVM纳入疫苗的明确国家政策及执行能力。
  • 关于VVM及其对疫苗项目效率、安全性和成本影响的知识对转型国家的持续VVM需求至关重要。

研究设计与样本

  • 系统综述,检索2005年以来发表的英文和法文电子数据库、参考文献列表和灰色文献。
  • 纳入研究分析以下结局:VVM标签疫苗的可获得性和部署;免疫系统中VVM实践和认知;疫苗引入和决策过程;Gavi毕业和疫苗项目可持续性。

主要发现

  • VVM可获得性和使用受疫苗多来源采购及招标文件中VVM纳入疫苗规格程度的影响。
  • 卫生工作者和决策者对VVM及其对EPI项目影响的认知较高。
  • 关键国家机构如NRA和NPA能力薄弱可能影响VVM需求。
  • 国家在决定采用新疫苗时,疾病负担和疫苗价格可能比疫苗特性和呈现形式更重要。
  • 国家 largely 依赖WHO和PAHO等技术伙伴的建议和推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The vaccine vial monitor (VVM) registers cumulative heat exposure on vaccines over time. As low- and lower-middle-income countries transition beyond support from the Global Alliance for Vaccines and Immunization (Gavi), they will assume full responsibility for vaccine financing and procurement. It is unclear to what extent countries transitioning out of Gavi support will continue to include VVMs on their vaccines. This paper aims to systematically review evidence on VVM availability and use in low- and middle-income countries to document factors behind global access to and country demand for VVMs. Such results could help identify actions needed to ensure continued use of VVMs in countries that transition out of Gavi support. METHODS: We performed a systematic review of electronic databases, reference lists, and grey literature in English and French languages with publication dates from 2005 onwards. The studies included were analyzed for the following outcomes: (1) availability and deployment of VVM-labeled vaccines; (2) VVM practices and perceptions in the immunization system; (3) vaccine introduction and decision-making processes; (4) Gavi graduation and vaccine program sustainability. RESULTS: The study found that VVM availability and use was affected by multiple sourcing of vaccines and the extent to which VVM was included in the vaccine specification in the tendering documents when procuring vaccines. Knowledge about VVM and its impact on the EPI program was found to be high among health workers as well as decision-makers. However, the study also found that weak capacity in key national institutions such as NRA and NPA might impact on demand for VVM. As countries take decisions regarding the adoption of new vaccines, factors such as disease burden and vaccine price may assume greater importance than vaccine characteristics and presentation. Finally, the study found that countries rely largely on the advice and recommendations from technical partners such as WHO and PAHO. CONCLUSION: The study concludes that global access to and country demand for VVM are dependent on policy statements and recommendations about VVM by key policy institutions such as WHO and UNICEF. The study also concludes that despite Gavi-eligible countries having access to VVM-labeled vaccines, inclusion is often below 100%. Weak institutional capacity in key national agencies such as NRA and NPA seems to be a contributing factor, while other factors include the procurement of clear national policies on the inclusion of VVM on vaccines, along with the capacity to enforce the policy. Finally, the study concludes that knowledge about VVM and its impact on vaccine program efficiency, safety, and cost is critical for transitioning countries' continuous demand for VVM.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Eriksson P, Gessner BD, Jaillard P, et al. Vaccine vial monitor availability and use in low- and middle-income countries: A systematic review. Vaccine. 2017. PMID: 28364924. doi:10.1016/j.vaccine.2016.11.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。